PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy.

Int J Immunopathol Pharmacol · 2022 · PMC8891930 · PMID 35225058

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

did not reach statistical significancep = 0.051so close (0.05 < p ≤ 0.1)

Although it did not reach statistical significance, patients with PD-L1 negative tumors according to TPS score tended to demonstrate improved overall survival ( p = 0.051).

also in 111,027 other papers

showed a trendp = 0.051so close (0.05 < p ≤ 0.1)

However, we observed that positive PD-L1 immunostaining in TCs showed a trend of worse overall survival despite not achieving statistical significance ( p = 0.051) ( Figure 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.